Japanese pharma major Takeda (TYO: 4502) has presented positive interim results from a global Phase III trial of TAK-755.
The candidate is the first and only recombinant ADAMTS13 protein in development, providing a targeted therapy to treat the ultra-rare condition chronic thrombotic thrombocytopenic purpura (cTTP).
The chronic and debilitating blood clotting disorder is caused by a deficiency in the ADAMTS13 enzyme.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze